What autonomic signs are usually the first clue that an adult might have ADLD?

Early autonomic clues often appear in the 40‑50 year age range and include difficulty initiating urination or incomplete bladder emptying, constipation or fecal urgency, and a sudden drop in blood pressure when standing (orthostatic hypotension). Erectile dysfunction in men and, rarely, an inability to sweat (anhidrosis) can also be early red flags.

How is ADLD confirmed in the clinic?

Diagnosis relies on a combination of brain MRI showing symmetric white‑matter hyperintensities in the frontal and parietal lobes, and a molecular test that identifies a duplication or mutation of the LMNB1 gene. Electrophysiology (nerve conduction studies) may support demyelination, but genetic testing is the definitive test.

How quickly do movement problems progress, and can physical therapy slow the decline?

Motor symptoms typically start with leg stiffness or mild spasticity and evolve over several years to gait instability that may require a cane, then a walker, and eventually a wheelchair. Early and regular physical therapy focusing on stretching, balance training, and low‑impact aerobic exercise can preserve flexibility and reduce fall risk, although it does not halt the underlying demyelination.

What treatments help control the orthostatic hypotension and bladder problems that accompany ADLD?

There is no disease‑modifying therapy, so symptom management is key. For orthostatic hypotension, patients benefit from increased salt and fluid intake, compression stockings, and medications such as fludrocortisone or midodrine under physician supervision. Bladder dysfunction is often managed with timed voiding, pelvic floor exercises, and, when necessary, anticholinergic agents or intermittent catheterization.

Autosomal dominant leukodystrophy with autonomic disease

Adult‑onset autosomal dominant leukodystrophy presents with autonomic dysfunction followed by progressive movement impairment and demyelination.

Overview

Autosomal dominant leukodystrophy with autonomic disease (ADLD) belongs to the group of genetic disorders called leukodystrophies. Leukodystrophies are characterized by abnormalities of the nervous system’s white matter, which consists of nerve fibers covered by a fatty substance called myelin. Myelin insulates and protects nerve fibers and promotes the rapid transmission of nerve impulses.

Symptoms

The condition typically manifests in adulthood, most often in the fourth or fifth decade of life. Early signs involve the autonomic nervous system, followed by movement disturbances and, later, cognitive changes.

Autonomic manifestations

Difficulty with bowel and bladder function
Orthostatic hypotension (sharp drop in blood pressure upon standing)
Erectile dysfunction in men
Rarely, anhidrosis (inability to sweat), which can cause dangerously high body temperature

Movement and coordination problems

Muscle stiffness (spasticity) or weakness
Intention tremor (rhythmic shaking that worsens during movement)
Ataxia with dysmetria (impaired distance/scale judgment) and dysdiadochokinesia (difficulty with rapid alternating movements)
Initial involvement of the legs, later spreading to arms and face
Unsteady gait requiring a cane, walker, or wheelchair

Cognitive changes

Intelligence is usually preserved early on
Long‑standing disease may lead to decline in intellectual function (dementia)

Frequency

The exact prevalence of ADLD is unknown. At least 70 affected individuals have been described in the scientific literature, although the condition is likely underdiagnosed.

Causes & Risk Factors

ADLD is caused by mutations in the LMNB1 gene, which encodes the lamin B1 protein. Lamin B1 is an essential scaffolding component of the nuclear envelope and influences nuclear shape, DNA replication, and gene expression.

Nearly all cases result from an abnormal extra copy (duplication) of the LMNB1 gene, leading to overproduction of lamin B1. While lamin B1 is present in cells throughout the body, brain cells—particularly oligodendrocytes that produce myelin—are especially sensitive to its excess. Elevated lamin B1 reduces expression of genes involved in myelin production and hardens the nuclear envelope, ultimately impairing cell function and causing progressive demyelination.

Demyelination occurs in the central nervous system (brain and spinal cord) often years before motor symptoms appear. Spinal cord demyelination likely contributes to early autonomic signs, whereas cerebellar and corticospinal tract demyelination underlies the later movement disturbances.

Inheritance

This condition is inherited in an autosomal dominant manner, meaning a single altered copy of the gene in each cell is sufficient to cause the disorder. In most cases, an affected individual has one parent with the condition.

Other Names for This Condition

ADLD
Adult‑onset autosomal dominant leukodystrophy with autonomic symptoms
Autosomal dominant adult‑onset demyelinating leukodystrophy
LMNB1‑related adult‑onset autosomal dominant leukodystrophy

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Adult‑onset autosomal dominant demyelinating leukodystrophy

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD)

Catalog of Genes and Diseases (OMIM)

LEUKODYSTROPHY, DEMYELINATING, ADULT‑ONSET, AUTOSOMAL DOMINANT, TYPICAL; ADLDTY

Scientific Articles on PubMed

PubMed

References

Bartoletti‑Stella A, et al. Messenger RNA processing is altered in autosomal dominant leukodystrophy. Hum Mol Genet. 2015;24(10):2746‑56. doi:10.1093/hmg/ddv034.
Ferrera D, et al. Lamin B1 overexpression increases nuclear rigidity in autosomal dominant leukodystrophy fibroblasts. FASEB J. 2014;28(9):3906‑18. doi:10.1096/fj.13‑247635.
Finnsson J, et al. LMNB1‑related autosomal‑dominant leukodystrophy: Clinical and radiological course. Ann Neurol. 2015;78(3):412‑25. doi:10.1002/ana.24452.
Giorgio E, et al. A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult‑onset demyelinating leukodystrophy (ADLD). Hum Mol Genet. 2015;24(11):3143‑54. doi:10.1093/hmg/ddv065.
Giorgio E, et al. Analysis of LMNB1 duplications in autosomal dominant leukodystrophy provides insights into duplication mechanisms and allele‑specific expression. Hum Mutat. 2013;34(8):1160‑71. doi:10.1002/humu.22348.
Heng MY, et al. Lamin B1 mediates cell‑autonomous neuropathology in a leukodystrophy mouse model. J Clin Invest. 2013;123(6):2719‑29. doi:10.1172/JCI66737.
Padiath QS, et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet. 2006;38(10):1114‑23. doi:10.1038/ng1872.
Rolyan H, et al. Defects of Lipid Synthesis Are Linked to the Age‑Dependent Demyelination Caused by Lamin B1 Overexpression. J Neurosci. 2015;35(34):12002‑17. doi:10.1523/JNEUROSCI.1668‑15.2015.